Changchun High-tech: Subsidiary Fuk Xin Qi Bai Monoclonal Antibody Injection has received acceptance for registration clinical trial application of domestically produced drugs.

Changchun High-tech announced that its holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. has received a "Notice of Acceptance" from the National Medical Products Administration for the domestic production drug registration clinical trial application of Vuximabib single monoclonal antibody injection. Vuximabib is a fully human anti-interleukin-1 monoclonal antibody developed by Jinsai Pharmaceutical, intended for the treatment of non-infectious uveitis.